Proveca and BCWorld Healthcare announce the launch of the first licensed product in South Korea

Press release intended for investors only

20 March 2026 – Proveca and BCWorld Healthcare (hereinafter BCW) are pleased to announce the launch of Sialanar® (glycopyrronium) in South Korea today. Sialanar® is the first licensed product approved in South Korea for the symptomatic treatment of severe sialorrhea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

The South Korean launch forms part of Proveca’s international product launch programme for Sialanar®, aiming to increase access to medicines globally. Proveca is the innovator of Sialanar®, which received Paediatric-use Marketing Authorisation (PUMA) from the European Medicines Agency (EMA) and has since been launched across several European markets and more widely, including South America.

In March 2024, Proveca entered into a partnership agreement with BCW, granting BCW exclusive rights for the licensing and distribution of Sialanar® in South Korea. In October 2024, BCW subsequently submitted a New Drug Application (NDA) in South Korea for Sialanar®, with marketing authorisation granted by the Ministry of Food and Drug Safety (MFDS) in August 2025.

Glycopyrronium use is well established, with a known and predictable anticholinergic side effect profile. Adverse reactions are common with glycopyrronium due to its known pharmacodynamic anticholinergic effects. The most common adverse reactions are dry mouth (11%), constipation (20%), diarrhoea (18%), urinary retention (15%), flushing (11%) and nasal congestion (11%). Adverse reactions are more common with higher doses and prolonged use.

Dr Simon Bryson, CEO of Proveca, said: “We are delighted to collaborate with BCW as we continue expanding the international reach of Sialanar®. The launch in South Korea represents an important milestone in our global rollout and provides a valuable treatment option for paediatric patients with sialorrhoea. Together with BCW, we aim to help address an unmet medical need and improve the lives of more children.”

Steve Hong, CEO of BCWorld Healthcare, said: “We are delighted to collaborate with Proveca to make Sialanar® available in South Korea. Through this collaboration, we aim to provide an additional treatment option for paediatric patients with chronic neurological conditions while continuing to expand our specialty care portfolio.”